| 抗乙型肝炎病毒药物研发现状 |
| |
| 引用本文： | 陈大明,肖宏. 抗乙型肝炎病毒药物研发现状[J]. 药学服务与研究, 2006, 6(3): 193-196 |
| |
| 作者姓名： | 陈大明 肖宏 |
| |
| 作者单位： | 1. 中国科学院上海生命科学研究院上海生命科学信息中心,上海,200031;中国科学院研究生院,北京,100039
2. 中国科学院上海生命科学研究院上海生命科学信息中心,上海,200031 |
| |
| 摘 要： | 从1983年到2005年11月．被美国FDA批准用于慢性乙型肝炎治疗的有5种药物．但其在疗效和不良反应等方面均有一定的局限性。目前．一批用于治疗慢性乙型肝炎的新药正处于研发阶段，其中已进入临床试验后期的药物以核苷类似物为主。本文对已上市及进入临床试验的治疗乙型肝炎的药物进行了总结．并对已完成Ⅱ期临床试验的治疗慢性乙型肝炎的药物进行了评述。
|
| 关 键 词： | 肝炎,乙型,慢性 抗病毒药,核苷类似物 干扰素类 |
| 文章编号： | 1671-2838(2006)03-0193-04 |
| 收稿时间： | 2006-01-20 |
| 修稿时间： | 2006-04-26 |
Advances in drug research and development for the treatment of chronic hepatitis B |
| |
| CHEN Da-Ming,XIAO Hong. Advances in drug research and development for the treatment of chronic hepatitis B[J]. Pharmaceutical Care and Research, 2006, 6(3): 193-196 |
| |
| Authors: | CHEN Da-Ming XIAO Hong |
| |
| Affiliation: | 1. Shanghai Information Center for Life Sciences, Shanghai Institute for Biological Sciences, Chinese Academy of Sciences, Shanghai 200031, China; 2. Graduate School of the Chinese Academy of Sciences, Beijing 100039 ,China |
| |
| Abstract: | There were five drugs for the treatment of chronic hepatitis B approved by U.S.Food and Drug Administration(FDA) from 1983 to November 2005.However,their therapeutic limitations and side effects bring about the needs of new drug development.In this article,the drugs approved by FDA for treating chronic hepatitis B virus infection,as well as those under clinical trials,and the three drugs whose phase-2 clinical trials have been completed are reviewed. |
| |
| Keywords: | hepatitis B, chronic antiviral agents, nucleoside analogue interferon |
| 本文献已被 CNKI 维普 万方数据 等数据库收录！ |
|
